Hereditary angioedema (HAE) is associated with often unpredictable attacks. These may be painful and impact a person’s ability to perform daily activities, such as working or attending school. Attacks with laryngeal involvement may lead to death. Plasma-derived C1-esterase inhibitor (C1-INH) products constitute the main therapy for treating and preventing these attacks. Their utilization is rapidly increasing in Canada. Other non-plasma-derived products are also becoming available for this condition.
The purpose of this project includes the following elements: improving the understanding of the context of drug therapies’ use for the long-term prophylaxis of HAE attacks, quantifying the utilization of C1-INH products, determining the economic value of plasma-derived and non-plasma-derived products for the long-term prophylaxis of HAE attacks, and determining the budget impact of funding these therapies.